1-5 of 5 results for subject:Diabetes
Librarians' tools
- Search time
- 0.148 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:Diabetes
- We searched for
- subject_t:Diabetes OR subject_ses:9636
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of broadening the eligibility list for covid-19 antiviral treatments to include diabetics.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of broadening the eligibility list for covid-19 antiviral treatments to include diabetics.
The Therapeutics Clinical Review Panel considers the latest evidence on the patients most at risk of adverse outcomes from COVID-19 and provides advice to the National Health Service on the appropriate patient cohorts for new therapies. Patients with diabetes were not identified in the initial patient cohorts currently receiving these treatments.
However, the PANORAMIC study is gathering further evidence on those patients who would benefit from oral antiviral treatments, including patients with type 1 and type 2 diabetes. The results from this study will inform clinical access policy for these treatments through the NHS, including any expansion of the current eligible patient cohorts. Any such changes would be proposed by the NHS and agreed by the United Kingdom Chief Medical Officers.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of introducing legislative proposals to require the labelling of alcoholic drinks to include sugar content for the benefit of consumers with diabetes.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of introducing legislative proposals to require the labelling of alcoholic drinks to include sugar content for the benefit of consumers with diabetes.
The consultation to seek views on whether to introduce mandatory calorie labelling on prepacked alcohol and alcohol sold in on-trade businesses such as pubs and restaurants will be launched in due course. Respondents to the consultation will be able to provide suggestions for additional labelling requirements for consideration, such as sugar content.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact on diabetics and other clinically vulnerable people of all age groups of the proposed removal of the covid-19 self-isolation requirement in advance of the 24 March 2022 expiry date;...
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact on diabetics and other clinically vulnerable people of all age groups of the proposed removal of the covid-19 self-isolation requirement in advance of the 24 March 2022 expiry date;...
In line with the Public Sector Equality Duty, the Department must consider the impact of policy decisions on protected groups when changes to legislation are made. In the case of the self-isolation regulations, this was done alongside public health considerations ahead of the decision to remove these regulations.
From 24 February 2022, those who test positive for COVID-19 are no longer legally required to self-isolate. However, individuals with any of the main symptoms or a positive test result are advised to stay at home and avoid contact with other people.
The Government’s objective is to enable COVID-19 to be managed in a similar way to other respiratory illnesses, while minimising mortality and retaining the ability to respond if a new and more dangerous variant emerges. This is due to the success of the vaccination programme and pharmaceutical tools available to treat people who are most vulnerable to COVID-19.
To ask the Secretary of State for Health and Social Care, whether definitions used for clinically extremely vulnerable people or others asked to shield initially during the covid-19 outbreak included diabetes; and whether he has reviewed those definitions with regard to the inclusion of diabetes.
To ask the Secretary of State for Health and Social Care, whether definitions used for clinically extremely vulnerable people or others asked to shield initially during the covid-19 outbreak included diabetes; and whether he has reviewed those definitions with regard to the inclusion of diabetes.
The United Kingdom Chief Medical Officers identified specific medical conditions that placed people at the greatest risk of severe outcomes from COVID-19. It was determined that a blanket inclusion of everyone with a diagnosis of diabetes was not appropriate. As the shielding programme has now ended, there is no longer a centrally defined clinically extremely vulnerable group.
What recent assessment his Department has made of the effectiveness of continual glucose monitors in treating diabetes.
What recent assessment his Department has made of the effectiveness of continual glucose monitors in treating diabetes.
The Department has not made any recent assessment. Commissioning decisions for the adoption of technology products in diabetes are guided by authoritative, evidence-based guidance from the National Institute for Health and Care Excellence (NICE).
NICE has made a number of recommendations on continuous glucose monitoring in its suite of guidelines on diabetes, which are currently being updated. NICE will consider the evidence on and expects to publish its updated guidance in March 2022.